News | April 01, 2025
Lonza implements streamlined operating model
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Subscribe To Our Newsletter & Stay Updated
